Etoposide induces cell death via mitochondrial-dependent actions of p53

Cancer Cell International

Volumn 15, Issue 1, 2015, Pages

  Jamil, Sarwat ^a   Lam, Irene ^a   Majd, Maryam ^a   Tsai, Shu Huei ^a   Duronio, Vincent ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

DNA damage; Fibroblast; Mitochondria; P53 acetylation; Transcription

Indexed keywords

ETOPOSIDE; PIFITHRIN ALPHA; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; EMBRYO CELL; FIBROBLAST CULTURE; FLOW CYTOMETRY; INTRACELLULAR SIGNALING; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 84938572579     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/s12935-015-0231-z     Document Type: Article

References (46)

1. Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet. 16(Spec No 1):R67-R72. doi: 10.1093/hmg/ddm052
2. Jiang L, Sheikh MS, Huang Y (2010) Decision Making by p53: Life versus Death. Mol Cell Pharmacol 2(2):69-77
3. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54(8):2095-2097
4. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA et al (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9(6):1799-1805
5. Zhan Q, Bieszczad CK, Bae I, Fornace AJ Jr, Craig RW (1997) Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene 14(9):1031-1039. doi: 10.1038/sj.onc.1200927
6. Miyashita T, Harigai M, Hanada M, Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54(12):3131-3135
7. Speidel D, Helmbold H, Deppert W (2006) Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene 25(6):940-953. doi: 10.1038/sj.onc.1209126
8. Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD (2008) Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci USA 105(4):1215-1220. doi: 10.1073/pnas.0706764105
9. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303(5660):1010-1014. doi: 10.1126/science.1092734
10. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309(5741):1732-1735
11. Golubovskaya VM, Cance WG (2013) Targeting the p53 pathway. Surg Oncol Clin N Am 22(4):747-764. doi: 10.1016/j.soc.2013.06.003
12. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285(5434):1733-1737
13. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I et al (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2(9):474-479. doi: 10.1038/nchembio809
14. Leu JI, Pimkina J, Frank A, Murphy ME, George DL (2009) A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 36(1):15-27. doi: 10.1016/j.molcel.2009.09.023
15. Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB et al (1996) Topoisomerase II Etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem 271(46):29238-29244
16. Clifford B, Beljin M, Stark GR, Taylor WR (2003) G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res 63(14):4074-4081
17. Jamil S, Mojtabavi S, Hojabrpour P, Cheah S, Duronio V (2008) An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. Mol Biol Cell 19(8):3212-3220. doi: 10.1091/mbc.E07-11-1171
18. Relling MV, Mahmoud HH, Pui CH, Sandlund JT, Rivera GK, Ribeiro RC et al (1996) Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 14(2):399-404
19. Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, Wolff SN (1984) Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res 44(1):379-382
20. Minami H, Ando Y, Sakai S, Shimokata K (1995) Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. J Clin Oncol 13(1):191-199
21. Jamil S, Stoica C, Hackett TL, Duronio V (2010) MCL-1 localizes to sites of DNA damage and regulates DNA damage response. Cell Cycle 9(14):2843-2855
22. Komarova EA, Gudkov AV (2001) Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol 62(6):657-667
23. Murphy PJ, Galigniana MD, Morishima Y, Harrell JM, Kwok RP, Ljungman M et al (2004) Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 279(29):30195-30201. doi: 10.1074/jbc.M403539200
24. Sohn D, Graupner V, Neise D, Essmann F, Schulze-Osthoff K, Janicke RU (2009) Pifithrin-alpha protects against DNA damage-induced apoptosis downstream of mitochondria independent of p53. Cell Death Differ 16(6):869-878. doi: 10.1038/cdd.2009.17
25. Gary RK, Jensen DA (2005) The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. Mol Pharm 2(6):462-474. doi: 10.1021/mp050055d
26. Leu JI, George DL (2007) Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev 21(23):3095-3109. doi: 10.1101/gad.1567107
27. Wolff S, Erster S, Palacios G, Moll UM (2008) p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res 18(7):733-744. doi: 10.1038/cr.2008.62
28. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11(3):577-590
29. Leu JI, Dumont P, Hafey M, Murphy ME, George DL (2004) Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6(5):443-450. doi: 10.1038/ncb1123
30. Ubersax JA, Woodbury EL, Quang PN, Paraz M, Blethrow JD, Shah K et al (2003) Targets of the cyclin-dependent kinase Cdk1. Nature 425(6960):859-864. doi: 10.1038/nature02062
31. Ding H, Duan W, Zhu WG, Ju R, Srinivasan K, Otterson GA et al (2003) P21 response to DNA damage induced by genistein and etoposide in human lung cancer cells. Biochem Biophys Res Commun. 305(4):950-956
32. Nilsson I, Hoffmann I (2000) Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 4:107-114
33. Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2(1):21-32. doi: 10.1038/35048096
34. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366(6456):701-704. doi: 10.1038/366701a0
35. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20(15):1803-1815. doi: 10.1038/sj.onc.1204252
36. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL et al (1998) Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17(1):159-169. doi: 10.1093/emboj/17.1.159
37. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G et al (2013) A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 11(3):219-229. doi: 10.1158/1541-7786.MCR-12-0547-T
38. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E et al (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20(6):1331-1340. doi: 10.1093/emboj/20.6.1331
39. Olsson A, Manzl C, Strasser A, Villunger A (2007) How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 14(9):1561-1575. doi: 10.1038/sj.cdd.4402196
40. Kobet E, Zeng X, Zhu Y, Keller D, Lu H (2000) MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci USA 97(23):12547-12552. doi: 10.1073/pnas.97.23.12547
41. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E et al (2002) MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 21(22):6236-6245
42. Appella E, Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem/FEBS 268(10):2764-2772
43. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G et al (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18(7):1805-1814. doi: 10.1093/emboj/18.7.1805
44. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24(15):6728-6741. doi: 10.1128/MCB.24.15.6728-6741.2004
45. Vaseva AV, Moll UM (2009) The mitochondrial p53 pathway. Biochim Biophys Acta 1787(5):414-420. doi: 10.1016/j.bbabio.2008.10.005
46. Ljungman M, Lane DP (2004) Transcription-guarding the genome by sensing DNA damage. Nat Rev Cancer 4(9):727-737. doi: 10.1038/nrc1435